JP2015231997A5 - - Google Patents

Download PDF

Info

Publication number
JP2015231997A5
JP2015231997A5 JP2015132999A JP2015132999A JP2015231997A5 JP 2015231997 A5 JP2015231997 A5 JP 2015231997A5 JP 2015132999 A JP2015132999 A JP 2015132999A JP 2015132999 A JP2015132999 A JP 2015132999A JP 2015231997 A5 JP2015231997 A5 JP 2015231997A5
Authority
JP
Japan
Prior art keywords
formulation
histidine
mannitol
formulation according
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015132999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015231997A (ja
Filing date
Publication date
Priority claimed from EP08170884A external-priority patent/EP2196476A1/en
Application filed filed Critical
Publication of JP2015231997A publication Critical patent/JP2015231997A/ja
Publication of JP2015231997A5 publication Critical patent/JP2015231997A5/ja
Withdrawn legal-status Critical Current

Links

JP2015132999A 2008-12-10 2015-07-01 抗体製剤 Withdrawn JP2015231997A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
EP08170884.4 2008-12-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011540063A Division JP6143416B2 (ja) 2008-12-10 2009-12-09 抗体製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018102715A Division JP2018168158A (ja) 2008-12-10 2018-05-29 抗体製剤

Publications (2)

Publication Number Publication Date
JP2015231997A JP2015231997A (ja) 2015-12-24
JP2015231997A5 true JP2015231997A5 (enExample) 2016-02-25

Family

ID=40637230

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011540063A Active JP6143416B2 (ja) 2008-12-10 2009-12-09 抗体製剤
JP2015132999A Withdrawn JP2015231997A (ja) 2008-12-10 2015-07-01 抗体製剤
JP2018102715A Withdrawn JP2018168158A (ja) 2008-12-10 2018-05-29 抗体製剤
JP2020133477A Active JP7286595B2 (ja) 2008-12-10 2020-08-06 抗体製剤
JP2023085464A Pending JP2023109938A (ja) 2008-12-10 2023-05-24 抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011540063A Active JP6143416B2 (ja) 2008-12-10 2009-12-09 抗体製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018102715A Withdrawn JP2018168158A (ja) 2008-12-10 2018-05-29 抗体製剤
JP2020133477A Active JP7286595B2 (ja) 2008-12-10 2020-08-06 抗体製剤
JP2023085464A Pending JP2023109938A (ja) 2008-12-10 2023-05-24 抗体製剤

Country Status (31)

Country Link
US (3) US20110236398A1 (enExample)
EP (4) EP2196476A1 (enExample)
JP (5) JP6143416B2 (enExample)
KR (2) KR101762966B1 (enExample)
CN (3) CN104399076B (enExample)
AU (1) AU2009324371B2 (enExample)
BR (1) BRPI0922730A2 (enExample)
CA (1) CA2745938C (enExample)
CL (1) CL2011001406A1 (enExample)
CO (1) CO6361952A2 (enExample)
CY (2) CY1117735T1 (enExample)
DK (2) DK2376533T3 (enExample)
EC (1) ECSP11011192A (enExample)
ES (2) ES2900624T3 (enExample)
HR (2) HRP20211899T1 (enExample)
HU (2) HUE028408T2 (enExample)
IL (3) IL264316B2 (enExample)
LT (1) LT3072906T (enExample)
MA (1) MA33023B1 (enExample)
MX (1) MX2011006242A (enExample)
MY (2) MY166050A (enExample)
NZ (1) NZ592918A (enExample)
PE (1) PE20120342A1 (enExample)
PL (2) PL2376533T3 (enExample)
PT (2) PT2376533T (enExample)
RU (2) RU2745601C2 (enExample)
SI (2) SI2376533T1 (enExample)
SM (1) SMT201600222B (enExample)
TN (1) TN2011000229A1 (enExample)
WO (1) WO2010066762A1 (enExample)
ZA (1) ZA201103362B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CA2789061A1 (en) 2010-02-26 2011-09-01 Henrik Parshad Stable antibody containing compositions
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
RS66182B1 (sr) 2010-05-28 2024-12-31 Novo Nordisk As Stabilne višedozne kompozicije koje sadrže antitelo i konzervans
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2011301803A1 (en) 2010-09-17 2013-03-21 Baxalta GmbH Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
SI3590949T1 (sl) 2010-10-01 2022-09-30 Modernatx, Inc. Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
WO2013123114A2 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
HRP20191333T1 (hr) * 2012-03-16 2019-10-18 Regeneron Pharmaceuticals, Inc. Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
HK1208231A1 (en) * 2012-09-20 2016-02-26 Morphosys Ag Treatment for rheumatoid arthritis
WO2014078502A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2906101A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗il-4/抗il-13之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CN108367072B (zh) 2015-12-07 2022-12-27 默克专利股份有限公司 含抗-pd-l1抗体avelumab的水性药物制剂
MA45450B1 (fr) * 2016-06-27 2021-04-30 Morphosys Ag Formulations d'anticorps anti-cd19
US20210292404A1 (en) * 2016-07-21 2021-09-23 Novartis Ag Use of il-1beta binding antibody canakinumab for treating or allevating symptoms pulmonary sarcoidosis
RU2019112680A (ru) * 2016-09-27 2020-10-29 Фрезениус Каби Дойчланд Гмбх Жидкая фармацевтическая композиция
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトMUC1抗体Fabフラグメント
CA3061874A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
MX2020002813A (es) * 2017-09-13 2020-07-21 Novartis Ag Uso de anticuerpos de union a il-1b para el tratamiento de la hepatitis alcoholica.
AU2019237252A1 (en) * 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
EP3795590A4 (en) 2018-05-17 2022-05-04 Astellas Pharma Inc. COMPLEX WITH ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
CN112839683B (zh) 2018-10-10 2023-11-14 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
US11634485B2 (en) * 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业(上海)股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
WO2022135395A1 (zh) * 2020-12-22 2022-06-30 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
DK2275119T3 (da) 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
ES2319866T3 (es) * 2000-06-29 2009-05-14 Abbott Laboratories Anticuerpos de especificidad dual y metodos de fabricacion y uso.
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004091658A1 (en) * 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
TW200638943A (en) * 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
HUE028410T2 (en) * 2005-03-08 2016-12-28 Pfizer Prod Inc Anti-ctla-4 antibody compositions
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
BRPI0617830B8 (pt) 2005-10-26 2021-05-25 Novartis Ag uso de um anticorpo de ligação il-1beta e composições farmacêuticas compreendendo o mesmo
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
EP2094729A1 (en) * 2006-12-11 2009-09-02 F.Hoffmann-La Roche Ag Abeta antibody parenteral formulation
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Similar Documents

Publication Publication Date Title
JP2015231997A5 (enExample)
TWI725973B (zh) 抗-cgrp抗體調配物
JP7473603B2 (ja) 液体医薬組成物
HRP20241131T1 (hr) Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode
JP2021504372A5 (enExample)
JP2014514346A5 (enExample)
RU2015132431A (ru) Составы, содержащие антитела
JP7229999B2 (ja) ダプトマイシン製剤
JP2016520075A5 (enExample)
JP2019504086A5 (enExample)
PE20170780A1 (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
JP2019509311A5 (enExample)
JP2013079270A5 (enExample)
JP2016505572A5 (enExample)
RU2011151286A (ru) Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
JP2016535065A (ja) 熱安定性ワクチン製剤及びマイクロニードル
JP2019504882A5 (enExample)
CN101631563B (zh) 含有流感疫苗的冻干制剂及其制备方法
IL294463A (en) Methods for treating or preventing eye conditions
JP2017531682A5 (enExample)
RU2016105462A (ru) Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
JP2016539921A5 (enExample)
JP2017514868A5 (enExample)